NCT04994431 (POUR) is a Phase 4 clinical trial of Tamsulosin Hydrochloride in Thoracic Diseases, sponsored by University of Massachusetts, Worcester.

Who is sponsoring NCT04994431?

NCT04994431 is sponsored by University of Massachusetts, Worcester.

What drugs are being tested in NCT04994431?

Interventions in NCT04994431: Tamsulosin Hydrochloride.

What condition does NCT04994431 study?

NCT04994431 studies Thoracic Diseases, Urinary Retention.

Is NCT04994431 still recruiting?

NCT04994431 is currently terminated. Last updated 7 November 2024.

Are results published for NCT04994431?

Yes — primary outcome results have been posted to ClinicalTrials.gov. See the outcomes section above for details.

Last reviewed 2024-11-07 · How we verify

NCT04994431: POUR

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Post-Operative Urinary Retention (POUR) in Thoracic Surgery Patients Receiving Prophylactic Tamsulosin

Terminated Phase 4 Results posted Last updated 7 November 2024

What this trial tests

Phase 4 trial testing Tamsulosin Hydrochloride in Thoracic Diseases in 109 participants. Terminated before completion.

Timeline

1 August 2021

Primary endpoint
4 October 2023

4 October 2023

Quick facts

Lead sponsor	University of Massachusetts, Worcester
Phase	Phase 4
Status	Terminated
Study type	INTERVENTIONAL
Allocation	non randomized
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	109
Start date	1 August 2021
Primary completion	4 October 2023
Estimated completion	4 October 2023
Sites	1 location across United States

Drugs / interventions tested

Tamsulosin Hydrochloride — full drug profile →

Conditions studied

Thoracic Diseases — all drugs for Thoracic Diseases →
Urinary Retention — all drugs for Urinary Retention →

Sponsor

University of Massachusetts, Worcester

Who can join

60 and older, male only, with Thoracic Diseases or Urinary Retention. Patients with the condition only — healthy volunteers not accepted.

Results — posted to ClinicalTrials.gov

Per-arm endpoint measurements with 95% confidence intervals where reported. Source: trial results section.

Participants With Post-Operative Urinary Retention (Pour) Primary · 5 days

Proportion of Participants experiencing Post-Operative Urinary Retention (POUR) following thoracic surgery as compared to historic controls.

Group	Value	95% CI
Perioperative Tamsulosin Hydrochloride	1
Historical Comparator	32

Adverse events — posted to ClinicalTrials.gov

Time frame: 5 Days. Reporting threshold: 0%. Adverse-event reports describe events observed during the trial — not all are caused by the drug.

Perioperative Tamsulosin Hydrochloride

Serious: 1/7 (14%)

Deaths: 0/7

Historical Comparator

Serious: 0/101 (0%)

Deaths: 0/101

Serious adverse events (1 terms)

Reaction	System	Perioperative Tamsulosin H…	Historical Comparator
Aspiration	Respiratory, thoracic and mediastinal disorders	—	—

Most-reported serious reactions: Aspiration.

Data from ClinicalTrials.gov NCT04994431 adverse events section.

Sponsor's own description

Post-Operative Urinary Retention (POUR) in Thoracic Surgery is a prospective interventional study aiming to test the hypothesis that the prophylactic use of tamsulosin prior to thoracic surgery in high risk patients leads to reduce the rates of POUR.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of Tamsulosin Hydrochloride

Trials testing the same drug.

NCT06865430 — Management of Dysuria and Irritative Symptoms After HoLEP: a Prospective Study Evaluating the Efficacy of Alpha-Blocker · NA · recruiting
NCT06262048 — Prevention of Post Operative Urinary Retention After Thoracic Surgery Trial · Phase 2 · recruiting
NCT06867315 — The Safety and Effectiveness of Steep Pulse Therapy System for the Ablation of Benign Prostatic Hyperplasia · NA · recruiting
NCT04159077 — REduction of Post-Operative Urinary Retention With Tamsulosin Versus Placebo (REPOURT- P) Trial · Phase 3 · unknown
NCT05890235 — Efficacy and Safety of Ningmitai Capsule in Patients With Chronic Prostatitis/Chronic Pelvic Pain Syndrome · Phase 4 · completed

Other recruiting trials for Thoracic Diseases

Currently open trials in the same condition.

NCT07250230 — Effect of Perioperative High-dose Transdermal Nicotine Patch on Pain Sensitivity Among Male Abstinent Tobacco Smokers Un · NA · recruiting
NCT05521789 — Erector Spinae Block for Thoracic Surgery · Phase 4 · recruiting
NCT04630496 — Geriatric Thoracic Surgery Ambulation Challenge · NA · recruiting

Other University of Massachusetts, Worcester trials

Trials by the same sponsor.

NCT07431528 — Dementia and Storytelling in Vietnam · NA · not yet recruiting
NCT07060664 — Study on Outcomes of Proximal Humerus Fractures · NA · not yet recruiting
NCT07520110 — Metformin to Attenuate Progressive Respiratory Decline in Idiopathic Pulmonary Fibrosis · Phase 3 · not yet recruiting
NCT06100809 — Does Fatigue Coaching Improve Functioning and Fatigue in Resident Night Shifts · NA · not yet recruiting
NCT06246539 — Impact of a Virtual Reality-based Mindfulness Program on Clinician Wellness · NA · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04994431 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by University of Massachusetts, Worcester
Last refreshed: 7 November 2024

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04994431.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing